Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
150%(3 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
1
25%
Ph not_applicable
1
25%
Ph phase_4
2
50%

Phase Distribution

0

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Terminated(2)

Detailed Status

Completed2
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 21 (25.0%)
Phase 42 (50.0%)
N/A1 (25.0%)

Trials by Status

completed250%
withdrawn125%
terminated125%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_2

H-22411: BOTOX® for Peyronie's Disease

NCT00812838
completedphase_4

Ultrasound-guided Adductor Canal Block for Total Knee Replacement

NCT02100579
terminatedphase_4

Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction

NCT02008617
withdrawnnot_applicable

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion

NCT00616850

Clinical Trials (4)

Showing 4 of 4 trials
NCT00812838Phase 2

H-22411: BOTOX® for Peyronie's Disease

Completed
NCT02100579Phase 4

Ultrasound-guided Adductor Canal Block for Total Knee Replacement

Completed
NCT02008617Phase 4

Analgesic Benefits of Genicular Nerve Blocks of the Posterior Knee for Patients Undergoing ACL Reconstruction

Terminated
NCT00616850Not Applicable

Treatment of Postoperative Pain After Total Knee Arthroplasy Using Intravenous Lidocaine Infusion

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
4